From Pets to Profits

Three kinds of capital are circling this profession. They want the same thing — a return — but they behave very differently once they own your clinic.

• Venture capital — the bettors. In 2021 they wouldn't talk unless they saw a 40× return; one or two home runs make the whole fund. In vet med: telehealth, AI scribes, devices (Chewy was VC once).
• Private equity — the buyers. They want 3–5× and usually a 3–7-year exit. They took vet med from under 10% corporate-owned to 30–50% in a decade. These are the clinic consolidators.
• Institutional capital — the whales. BlackRock, Vanguard and State Street manage about $26 trillion and are the top shareholder in roughly 80% of the S&P 500. They buy the PE firms' portfolios — when AmeriVet recapitalized at ~$1.6B, the buyers were AEA Investors and Abu Dhabi's sovereign wealth fund, ADIA.

Pet spending is still huge — but in 2026 the industry quietly lowered its own expectations, and the deal market followed.

• Rates broke the model. When interest rates spiked in 2022, PE's borrowed-money math stopped working. Corporate deal flow fell by as much as 60%.
• Visits normalized. The COVID pet boom faded, growth slowed, and valuations reset.

The part corporates don't put on the pitch slide. Two practices can be offered the "same" EBITDA multiple and be wildly different deals — because the blend changed.

• Earn-outs now stack conditions. Hit gross-receipts goals and keep a newly hired DVM employed a full year — inside a 15-month window — or the money never releases. Sellers are doing the buyer's hiring; the skin in the game can be $500K to keep two or three associates.
• The equity is often speculative. It can lose value, and sometimes gets bought back at a discount once you stop working.
• Corporates stopped negotiating EBITDA. It used to be a conversation. Now it's "this is our number, take it or leave it."
• Know who's across the table. The person calling on you is frequently a former equipment rep, not a finance person — there to get an LOI signed, not to move a number. Bring your own valuation expert.

• The hidden structure. Most West-Coast states bar non-DVMs from owning clinics. So corporates set up a captive company owned by a figurehead veterinarian (often titled "chief veterinary officer") that holds the clinical goodwill — while a management contract bleeds the profits out to the corporate. It sounds suspicious; it's standard, lifted straight from pharmacy and human medicine.
• Don't confuse multi-practice with corporate. Plenty of veterinarian-owned multi-practice groups are excellent. Judge every offer on its own: when is their liquidity event, and how many clinics do they want before they stop?
• Consolidation can simply stop. Tyler once sold ~50 compounding pharmacies a year to private equity — then one CVS roll-up hit and it went to zero. "They don't transact anymore." The human-medicine version of this story ended in the largest hospital bankruptcy ever (Steward, 2024).

The buzziest change in years — and the most actionable thing in this briefing if you employ or are an associate DVM in Washington.

• Almost all employee non-competes are void as of June 2027 — the time-and-radius bans — regardless of the old ~$126K salary threshold. Non-competes tied to the sale of a practice still stand.
• Employers must give notice that non-competes are void (by Oct 2027) or risk penalties — up to $5,000 plus the employee's attorney fees.
• The hidden leverage for associates: existing non-competes hold until 2027, but corporates rarely sue — it's bad for morale, business, and recruiting. You can often get released early for a severance or a signed waiver. It's always on the table.
• This is where the market's going. California has had no non-competes for years and it's been fine; Oregon will likely follow.

Where it's heading — and the one number that captures it.

• "Too profitable to sell." Owners of 1.5–2 doctor clinics run the math — "if all the equity and earn-outs pay, I'd do okay… but I'd make about the same working two more years and selling to my associates." So they keep it.
• Comp is being redesigned. "20% of production, end of story" is over. Profit-share and bonus models win younger doctors without piling risk on the owner — and out-compete corporate signing bonuses.
• Data & AI is the independent's edge. Nimble practices with fewer decision-makers that mine their PIMS and move fast will win. Switching systems is getting easier — soon it'll be "like changing your scheduling software, not open-heart surgery."

What this means for you